Core Viewpoint - The announcement details the completion and results of a share reduction plan by a major shareholder, Ruizhong Life Insurance Co., Ltd., which reduced its stake in Jiangsu Hualan Pharmaceutical Materials Co., Ltd. by 1.00% through a series of transactions [1][2]. Summary by Sections Shareholder Reduction Plan - Ruizhong Life Insurance planned to reduce its holdings by up to 1,263,089 shares (1.00% of total shares) through centralized bidding and up to 2,526,178 shares (2.00% of total shares) via block trading within a specified period [1]. - The actual reduction amounted to 1,263,000 shares, representing 0.7692% of the total share capital, with an average price range of 30.08 to 31.92 yuan per share [1]. Shareholding Changes - Prior to the reduction, Ruizhong Life held 21,956,522 shares (17.38% of total shares), which decreased to 21,459,922 shares (16.99% of total shares) post-reduction [1]. - After the company's capital increase and distribution of dividends, Ruizhong Life's holdings increased to 26,901,579 shares, reflecting a change in ownership percentage [2]. Compliance and Commitments - Ruizhong Life has adhered to its commitments regarding shareholding and reduction intentions, ensuring no violations of relevant regulations or agreements [3][4]. - The company confirmed that all shares held were free from any pledges or disputes, and it has complied with the lock-up period and reduction procedures as stipulated [3][4].

Core Viewpoint - The company, Jiangsu Hualan Pharmaceutical Materials Co., Ltd., has announced a share repurchase plan using raised funds, self-owned funds, and self-raised funds, aiming to repurchase up to 1% of its shares through centralized bidding [1][2]. Summary by Sections Share Repurchase Plan - The company plans to use a total of no less than RMB 100 million and no more than RMB 200 million for the repurchase, with raised funds between RMB 30 million and RMB 60 million, and self-owned and self-raised funds also contributing [2]. - The repurchased shares will be used for cancellation to reduce registered capital and for employee stock ownership plans or equity incentives [2]. Price Adjustment - Following the implementation of the 2024 annual equity distribution, the maximum repurchase price has been adjusted from RMB 45.50 per share to RMB 34.84 per share, effective from July 14, 2025 [3]. Progress of Share Repurchase - As of August 20, 2025, the company has repurchased a total of 1,809,153 shares, accounting for 1.10% of the total share capital, with a maximum transaction price of RMB 33.959 per share and a minimum transaction price of RMB 28.700 per share [4][5]. Compliance and Future Actions - The company confirms that the share repurchase actions comply with relevant regulations and will continue to implement the repurchase plan based on market conditions, fulfilling disclosure obligations as required [6].

Core Viewpoint - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. has announced a share repurchase plan using raised funds, self-owned funds, and self-raised funds through centralized bidding, with a total repurchase amount between RMB 100 million and RMB 200 million [2][3]. Summary by Sections Share Repurchase Plan - The company plans to use a total of no less than RMB 100 million and no more than RMB 200 million for the share repurchase, with at least RMB 30 million and no more than RMB 60 million coming from raised funds [2]. - The repurchased shares will be used for cancellation to reduce registered capital and for employee stock ownership plans or equity incentives [2]. Price Adjustment - Following the implementation of the 2024 annual equity distribution, the maximum repurchase price has been adjusted from RMB 45.50 per share to RMB 34.84 per share, effective from July 14, 2025 [3]. Repurchase Details - The repurchase plan includes a target quantity of shares to be repurchased ranging from 2,009,185 to 4,018,369 shares, which represents approximately 1.75% to 3.50% of the company's total shares [4]. - As of July 31, 2025, the company has not yet implemented the share repurchase [4].

Core Viewpoint - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. has approved the use of idle raised funds and self-owned funds for cash management, with a total limit of up to RMB 1.3 billion, which includes RMB 950 million from raised funds and RMB 350 million from self-owned funds [2][4]. Group 1: Cash Management Approval - The company held meetings on November 29, 2024, and December 18, 2024, to approve the cash management proposal [2]. - The cash management period is set for 12 months from the date of shareholder approval [2]. Group 2: Redemption of Cash Management Products - The company has redeemed cash management products using idle raised funds, with specific details on the amounts and types of products involved [2][3]. - The redemption includes various structured deposit products from banks such as China Everbright Bank and Ningbo Bank [3][6]. Group 3: Cash Management Situation - The company has utilized idle raised funds and self-owned funds for cash management, with a total of RMB 1.013 billion remaining in cash management products, including RMB 818 million from raised funds and RMB 195 million from self-owned funds [8]. - The cash management activities are conducted without affecting the company's daily operations and the normal progress of investment projects [5][6]. Group 4: Related Party Relationships - There are no related party relationships between the company and the banks involved in the cash management products [3].

Core Viewpoint - The report outlines the approval and details regarding the lifting of restrictions on shares of Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. prior to its initial public offering (IPO) and the subsequent listing of these shares for trading [1][2]. Summary by Sections 1. Type of Restricted Shares - The company issued 33,666,667 shares during its IPO, with a total share capital of 134,666,667 shares post-IPO. Of these, 103,765,403 shares were subject to restrictions, representing 77.05% of the total. The current release involves 1,756,450 shares, accounting for 1.30% of the total share capital [1][2]. 2. Changes in Share Capital - Following the issuance of restricted shares, the total share capital increased to 135,786,667 shares after the granting of 1,120,000 restricted shares on March 16, 2023. The company also canceled 6,412,625 shares held in a repurchase account, leading to a total of 126,308,942 shares as of the report date [3][4]. 3. Commitments and Compliance - The controlling shareholder, Jiangyin Hualan Electromechanical Technology Co., Ltd., committed to not pledging or transferring shares for 36 months post-IPO. If the stock price falls below the IPO price for 20 consecutive trading days, the lock-up period is extended by 6 months. All commitments have been adhered to without any violations [5][6][9]. 4. Listing and Trading Arrangements - The shares will be available for trading starting May 15, 2025. A total of 37,827,846 shares will be released, which is 29.9487% of the total share capital. The release involves four shareholders, with no shares being pledged or frozen [10][12]. 5. Share Structure Post-Release - After the release of restricted shares, the structure will reflect 38,032,821 restricted shares (30.11%) and 126,103,967 unrestricted shares (99.84%). The total share capital remains at 126,308,942 shares [11][12]. 6. Sponsor's Verification Opinion - The sponsor confirms that all shareholders have complied with their lock-up commitments and that the application for the release of restricted shares meets all regulatory requirements. The information disclosed regarding the release is deemed accurate and complete [13].

Group 1 - The major shareholder, Ruizhong Life Insurance Co., Ltd., plans to reduce its holdings in Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. by up to 3,789,267 shares, which accounts for 3.00% of the total share capital [1][2] - The reduction will occur within a three-month period from June 4, 2025, to September 3, 2025, with a trading window where no shares will be sold [1][2] - The reduction will be executed through centralized bidding and block trading, with a maximum of 1,263,089 shares (1.00% of total shares) sold via centralized bidding and 2,526,178 shares (2.00% of total shares) via block trading [1][2] Group 2 - Ruizhong Life Insurance Co., Ltd. has committed to not transferring or entrusting others to manage its shares for a period of 24 months following the initial public offering [3] - The company has confirmed that it has not violated any commitments regarding shareholding and has complied with relevant regulations [5]